Nature Communications (Jul 2024)

HuR controls glutaminase RNA metabolism

  • Douglas Adamoski,
  • Larissa M. dos Reis,
  • Ana Carolina Paschoalini Mafra,
  • Felipe Corrêa-da-Silva,
  • Pedro Manoel Mendes de Moraes-Vieira,
  • Ioana Berindan-Neagoe,
  • George A. Calin,
  • Sandra Martha Gomes Dias

DOI
https://doi.org/10.1038/s41467-024-49874-x
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 20

Abstract

Read online

Abstract Glutaminase (GLS) is directly related to cell growth and tumor progression, making it a target for cancer treatment. The RNA-binding protein HuR (encoded by the ELAVL1 gene) influences mRNA stability and alternative splicing. Overexpression of ELAVL1 is common in several cancers, including breast cancer. Here we show that HuR regulates GLS mRNA alternative splicing and isoform translation/stability in breast cancer. Elevated ELAVL1 expression correlates with high levels of the glutaminase isoforms C (GAC) and kidney-type (KGA), which are associated with poor patient prognosis. Knocking down ELAVL1 reduces KGA and increases GAC levels, enhances glutamine anaplerosis into the TCA cycle, and drives cells towards glutamine dependence. Furthermore, we show that combining chemical inhibition of GLS with ELAVL1 silencing synergistically decreases breast cancer cell growth and invasion. These findings suggest that dual inhibition of GLS and HuR offers a therapeutic strategy for breast cancer treatment.